dismiss

Clean Sweep Live Auction on Wed. May 1st. Click to view the full inventory

DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Pediatrics
SEARCH
Current Location:
>
> This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Comment
advertisement

 

advertisement

 

MRI Homepage

New study shows value of 7T MR for evaluating MS progression Can detect cortical lesions better than conventional scanners

Trice Imaging connects imaging devices of large chain healthcare provider Aleris Patients and physicians can view images on laptops, cell phones

The benefits of intraoperative MR Q&A with Dr. John Huston Mayo Clinic neuroradiologist discusses what the advanced capabilities mean for patients – as well as providers

Sound Imaging launches MR patient motion and detection system, SAMM MD Reduces repeat scans, prevents interruption to workflow

Gadolinium not required in 3T MR multiple sclerosis follow-up scans Longitude subtraction mapping just as sensitive: study

New MR methodology may distinguish benign and cancerous lymph nodes Could be used before surgery and help determine treatment

FDA gives thumbs-up to Genetesis MCG cardiac imaging system Measures magnetic fields produced by heart's electrical activity

BSWH to install Glassbeam's CLEAN blueprint to leverage machine uptime Will include integrated CMMS software by EQ2

NIH awards $1.8 million to Magnetic Insight for neurovascular MPI Detects magnetic nanoparticle tracers, enables deep-tissue imaging

Siemens focuses on digitalization at HIMSS Its expanded digital service portfolio will be on display

A new technique picks up relevantly
clinical tumors not detected by
ultrasound in prostate cancer scans

Surgeons should rely on visual interpretations and software for tumor detection, says study

by John R. Fischer , Staff Reporter
Researchers at University College London are recommending surgeons rely on both their visual interpretations and a software product used to identify clinically relevant prostate tumors not picked up by conventional ultrasound for biopsy guidance, based on the findings of a new study.

Deployed through a system called SmartTarget, the program enhances the technique of MR-targeted biopsies by relaying tumor information collected from the scans onto ultrasound images to identify malignancies and guide surgeons in removing them during biopsy procedures.

Story Continues Below Advertisement

THE (LEADER) IN MEDICAL IMAGING TECHNOLOGY SINCE 1982. SALES-SERVICE-REPAIR

Special-Pricing Available on Medical Displays, Patient Monitors, Recorders, Printers, Media, Ultrasound Machines, and Cameras.This includes Top Brands such as SONY, BARCO, NDS, NEC, LG, EDAN, EIZO, ELO, FSN, PANASONIC, MITSUBISHI, OLYMPUS, & WIDE.



"The software provides them with a clear target," Dr. Dean Barratt, professor of medical physics and biomedical engineering at the UCL Centre for Medical Image Computing, and the inventor of the SmartTarget system, said in a statement. "As MR-targeted biopsies require a very high degree of expertise and experience, we hope that the imagery displayed by SmartTarget will help to bring high accuracy prostate cancer diagnosis to a much wider range of patients and hospitals."

The use of MR scans in detecting the location of tumors prior to biopsies has boosted detection rates from 50 to 90 percent in the last five years.

The SmartTarget system leverages the approach by utilizing advanced image processing and machine learning to create a 3D model of the prostate and cancer from the MR scan of a patient, and then fuses it with ultrasound images during a biopsy. The combination highlights the area of concern, which otherwise would not appear in the ultrasound images.

Researchers applied the technology to 129 patients with suspected prostate cancer. Each underwent a biopsy that utilized SmartTarget and another in which the surgeon visually reviewed the scan, with each detecting 93 clinically significant prostate cancers and identifying up to 80 of the malignancies. Each approach missed 13 that were picked up by the other.

Based on their findings, the developers of the system recommend using it in conjunction with visual interpretations, predicting both together reducing the number of biopsies required, as well as unnecessary surgeries caused by over-diagnosis of less harmful cancers.

"With this study we now have hard data showing that SmartTarget is as good as a group of experts in targeting tumours in the prostate, and have a glimpse of how clinicians and computers will be working together in the future for the good of the patient," said co-senior author, Professor Mark Emberton, dean of UCL Medical Sciences, in a statement.

The SmartTarget software has been commercialized by SmartTarget, a company spun off of UCL's commercialization company, UCL Business PLC, and is in use at hospitals throughout the U.S. and the U.K.

The study was funded by the U.K. Department of Health and Social Care and Wellcome Health Innovation Challenge Funding.

The findings were published in the journal, European Urology.

MRI Homepage


You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2019 DOTmed.com, Inc.
ALL RIGHTS RESERVED